Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181141 | 1.00 | THRB (0.81) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5180385 | 1.00 | THRB (0.81) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5181792 | 0.91 | THRB (0.69) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5180248 | 0.89 | THRB (1.00) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5181006 | 0.89 | THRB (1.00) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5180244 | 0.89 | THRB (1.00) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5181206 | 0.88 | THRB (0.90) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5181202 | 0.88 | THRB (0.90) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6913964 | 0.86 | THRB (0.88) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6913971 | 0.86 | THRB (0.88) | THRBCYP3A4CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102036996-A | Bridged heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-27 | — | — | CN | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7268250-B2 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| EP-1439159-B1 | Process for producing optically active compound | KANTO KAGAKU (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-6809059-B2 | LANTHANUM AND NAPHTHOL CONTAINING COMPLEX FOR PERFORMING A MICHAEL ADDITION REACTION BETWEEN A BETA -DICARBONYL COMPOUND WITH A CYCLIC OR ACYCLIC ENONE | JOHNSON MATTHEY PLC (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20040176616-A1 | Process for producing optically active compound | KANTO KAGAKU KABUSHIKI KAISHA | 2004-09-09 | — | — | US | disclosed |
| EP-1439159-A1 | Process for producing optically active compound | Kanto Kagaku Kabushiki Kaisha (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-20020039961-A1 | Catalyst | JOHNSON MATTHEY PLC (GB) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176616-A1 | Process for producing optically active compound | OSTC, NPEPPS, PPOX | THRB 4628/4885CYP3A4 77/4885CYP2C9 513/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | THRB 4214/4885CYP3A4 319/4885CYP2C9 602/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | THRB 3757/4885CYP3A4 3381/4885CYP2C9 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.